Dihydrouracil
| Code | Size | Price |
|---|
| TAR-T4886-100mg | 100mg | £103.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T4886-1mL | 1 mL * 10 mM (in DMSO) | £107.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
5,6-Dihydrouracil is an intermediate breakdown product of uracil.
CAS:
504-07-4
Formula:
C4H6N2O2
Molecular Weight:
114.104
Pathway:
Metabolism
Purity:
0.9928
SMILES:
O=C1CCNC(=O)N1
Target:
Endogenous Metabolite
References
Assmann B , Hoffmann G F , Wagner L , et al. Dihydropyrimidinase deficiency and congenital microvillous atrophy: coincidence or genetic relation?[J]. Journal of Inherited Metabolic Disease, 1997, 20(5):681-8.
Sreekumar A, et al.Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762.
Andr? B. P. van KUILENBURG, Stroomer A E M , Lenthe H V , et al. New insights in dihydropyrimidine dehydrogenase deficiency: a pivotal role for beta-aminoisobutyric acid?[J]. Biochemical Journal, 2004, 379(1):119-24.
Hofmann U , Schwab M , Seefried S , et al. Sensitive method for the quantification of urinary pyrimidine metabolites in healthy adults by gas chromatography?tandem mass spectrometry[J]. Journal of Chromatography B, 2003, 791(1-2):371-380.
Grem J L . Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer[J]. Seminars in Oncology, 2005, 32(1):120-127.